Literature DB >> 1991250

Thymic carcinoma. A clinicopathologic study of 60 cases.

S Suster1, J Rosai.   

Abstract

The clinicopathologic features of 60 patients with thymic carcinoma were studied. Patients ranged in age from 10 to 76 years (mean, 46), of whom 24 were females and 36 were males. Overall survival at 1, 3, and 5 years was 56.6%, 40%, and 33.3%, respectively. The following morphologic features were correlated with survival: type of tumor margins; presence or absence of a lobular growth pattern; nuclear atypia; necrosis; mitotic activity; and histologic tumor type and grade. Eighty eight percent of patients with poorly circumscribed/infiltrating neoplasms died of their tumors as compared with 16.6% of patients with well-circumscribed neoplasms (P less than 0.0000). Of patients whose tumors had mitotic counts exceeding 10/10 high-power fields (HPF), 84.3% died, as compared with 21.4% of patients with lower mitotic counts (P less than 0.0000). Of patients whose tumors showed lack of lobular growth pattern, 91.6% died, as compared with 29% of those whose tumors had a lobular growth pattern (P less than 0.0000). Finally, 84.6% of patients whose tumors displayed a high-grade histology (lymphoepithelioma-like carcinoma, small cell/neuroendocrine carcinoma, clear cell carcinoma, sarcomatid carcinoma, and anaplastic/undifferentiated carcinoma) died of tumor, as compared with 0% of patients whose tumors were of low-grade histology (well-differentiated squamous carcinoma, mucoepidermoid carcinoma, and basaloid carcinoma) (P less than 0.0000). Evaluation of the various treatment modalities used to treat these patients did not yield any statistically significant correlations with survival. Two clinically distinct groups of patients were identified: one after a relatively favorable clinical course with long survival, and one after a rapidly fatal outcome. The morphologic features of the tumors in these patients correlated well with their clinical behavior; histologic type (and the grade to which it was assigned) constituted the most reliable and important predictor of prognosis.

Entities:  

Mesh:

Year:  1991        PMID: 1991250     DOI: 10.1002/1097-0142(19910215)67:4<1025::aid-cncr2820670427>3.0.co;2-f

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  93 in total

1.  Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging.

Authors:  Anya M Litvak; Kaitlin Woo; Sara Hayes; James Huang; Andreas Rimner; Camelia S Sima; Andre L Moreira; Maria Tsukazan; Gregory J Riely
Journal:  J Thorac Oncol       Date:  2014-12       Impact factor: 15.609

2.  Thymic papillo-tubular adenocarcinoma containing a cyst: report of a case.

Authors:  Koji Teramoto; Yo Kawaguchi; Tetsuo Hori; Mitsuaki Ishida; Masayuki Hashimoto; Shoji Kitamura; Makoto Motoishi; Jun Hanaoka; Noriaki Tezuka; Hidetoshi Okabe
Journal:  Surg Today       Date:  2012-03-11       Impact factor: 2.549

3.  Thymic carcinoma with a large cystic lesion.

Authors:  Shin-ichi Takeda; Hiroshi Hirano; Hajime Maeda; Noriyoshi Sawabata; Yoshitomo Okumura; Hiroki Asada
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2004-12

4.  Basaloid carcinoma of the thymus: report of a case.

Authors:  Yoshihisa Morisaki; Keigo Takagi; Shinji Sano; Takashi Furuya; Masahisa Ishikawa; Toshihiko Torigoe; Yoshifumi Ishii
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

5.  Thymic carcinoma with tumor thrombus into the superior vena cava.

Authors:  Y Kamikubo; N Shiiya; S Kubota; K Yasuda
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-05

6.  Clear cell carcinoma originating from ectopic thymus.

Authors:  Masaya Okuda; Cheng-Long Huang; Reiji Haba; Hiroyasu Yokomise
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-05-15

7.  Salvage chemotherapy with amrubicin and platinum for relapsed thymic carcinoma: experience in six cases.

Authors:  Tomonobu Koizumi; Toshihiko Agatsuma; Takashi Ichiyama; Toshiki Yokoyama; Atsuhito Ushiki; Yoshimichi Komatsu; Tsuyoshi Tanabe; Takashi Kobayashi; Sumiko Yoshikawa; Masanori Yasuo; Hiroshi Yamamoto; Keishi Kubo; Tsutomu Hachiya
Journal:  Med Oncol       Date:  2009-05-05       Impact factor: 3.064

8.  Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21.

Authors:  Y Hayashi; N Ishii; C Obayashi; K Jinnai; K Hanioka; Y Imai; H Itoh
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

9.  Computed tomography and thymoma: distinctive findings in invasive and noninvasive thymoma and predictive features of recurrence.

Authors:  A M Priola; S M Priola; M Di Franco; A Cataldi; S Durando; C Fava
Journal:  Radiol Med       Date:  2009-12-16       Impact factor: 3.469

10.  Early-stage thymic carcinoma: is adjuvant therapy required?

Authors:  Mitsuaki Sakai; Takuya Onuki; Masaharu Inagaki; Masatoshi Yamaoka; Shinsuke Kitazawa; Keisuke Kobayashi; Kesato Iguchi; Shinji Kikuchi; Yukinobu Goto; Masataka Onizuka; Yukio Sato
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.